NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...
Hence then, the article about trevi therapeutics announces pricing of 100 million underwritten offering of common stock was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock )
Also on site :
- Seizure of Russian-flagged oil tanker: what we know so far
- NYT ‘Connections’ Hints, Clues and Answers Today, Thursday, January 8, 2026
- Nestlé pulls baby milk batches amid safety fears